Tetra Bio Pharma Inc (TBPMQ)

[MERCURIAL]

Tetra Bio-Pharma Announces Results of Voting at Annual Shareholders' Meeting & Provides a Corporate Update

At the meeting, some key corporate highlights which were discussed, included:

Tetra is the only pharmaceutical company to have clinical studies for smoked marijuana;
The Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001. Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
Focused on expanding commercialization partnerships internationally for product pipeline - Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
The initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than what we expected for sales. We are now putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control. We will look at launching PPP001 using the ACMPR license by the end of summer. See press release announced April 17, 2017 for further information;
We are looking to start the Phase II clinical trials for PPP002 - Dronabinol XL in the next month; and
Investor outreach will be principally focused on the U.S. market going forward looking at targeting healthcare funds to potentially invest in Tetra. Communications strategy is to make very clear that Tetra is not a marijuana company but a pharmaceutical company.

http://www.marketwired.com/press-release/tetra-bio-pharma-announces-results-voting-annual-shareholders-meeting-provides-corporate-cse-tbp-2225752.htm